News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Increased Operating Profit by 32% in 2012


1/31/2013 9:23:33 AM

BAGSVAERD, DENMARK--(Marketwire - January 31, 2013) - Sales growth of 18% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 18% to 78.0 billion in Danish kroner and by 12% in local currencies.

* Sales of modern insulins increased by 21% (15% in local currencies).

* Sales of Victoza® increased by 58% (50% in local currencies).

* Sales in North America increased by 29% (19% in local currencies).

* Sales in International Operations increased by 18% (16% in local currencies).

Reported operating profit increased by 32% to DKK 29.5 billion including a 1.7 percentage points improvement in the gross margin. Measured in local currencies, operating profit increased by 20%.

Company announcement No 8 / 2013: http://hugin.info/2013/R/1674355/545183.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1674355]


CONTACTS FOR FURTHER INFORMATION
Media:
Mike Rulis
+45 4442 3573
Email Contact

Ken Inchausti (US)
+1 609 514 8316
Email Contact

Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact


Read at BioSpace.com

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES